{
    "clinical_study": {
        "@rank": "134385", 
        "arm_group": [
            {
                "arm_group_label": "Crestor tablet 20 mg", 
                "arm_group_type": "Experimental", 
                "description": "Crestor tablet 20 mg single--->wash out---->Glucophage SR tablet 750 mg single---->washout--->Glucophage SR tablet 750 mg, Crestor tablet 20 mg both"
            }, 
            {
                "arm_group_label": "Glucophage SR tablet 750 mg and Crestor tablet 20 mg both", 
                "arm_group_type": "Experimental", 
                "description": "Glucophage SR tablet 750 mg, Crestor tablet 20 mg both--->wash out---->Glucophage SR tablet 750 mg single------>washout--->Crestor tablet 20 mg single"
            }, 
            {
                "arm_group_label": "Glucophage SR tablet 750 mg", 
                "arm_group_type": "Experimental", 
                "description": "Glucophage SR tablet 750 mg single --->wash out---->Crestor tablet 20 mg single---->washout--->Glucophage SR tablet 750 mg, Crestor tablet 20 mg both"
            }
        ], 
        "brief_summary": {
            "textblock": "We investigate the potential pharmacokinetic drug-drug interaction between metformin\n      extended release and rosuvastatin in healthy male volunteers who receive metformin extended\n      release alone, rosuvastatin alone, and both together in a 3 period repeatedly."
        }, 
        "brief_title": "Evaluating a Pharmacokinetic Drug Interaction Between Metformin Hydrochloride and Rosuvastatin Calcium", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male volunteers, age 20 to 55 years.\n\n          2. The result of Body Mass Index(BMI) is not less than 19 kg/m2 , no more than 27 kg/m2\n\n          3. Subjects who have ability to comprehend the objectives, contents of study and\n             property of study drug before participating in trial and have willingness to sign of\n             informed consent in writing\n\n        Exclusion Criteria:\n\n          1. Presence of medical history or a concurrent disease that may interfere with treatment\n             and safety assessment or completion of this clinical study, including clinically\n             significant disorders in kidney, liver, cardiovascular system, respiratory system,\n             endocrine system, or neuropsychiatric system.\n\n          2. Glomerular filtration  rate is under 60ml/min which is calculated by serum creatinine\n             value.\n\n          3. Liver enzyme (AST, ALT) level exceeds one and a half times more than maximum normal\n             range.\n\n          4. Systolic blood pressure <90mmHg or Diastolic blood pressure < 60 mmHg, systolic blood\n             pressure \u2265 140 mmHg or diastolic blood pressure \u2265 90 mmHg(Sitting blood pressure)\n             during the screening procedure."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01775579", 
            "org_study_id": "HM-MERO-101"
        }, 
        "intervention": {
            "arm_group_label": [
                "Crestor tablet 20 mg", 
                "Glucophage SR tablet 750 mg and Crestor tablet 20 mg both", 
                "Glucophage SR tablet 750 mg"
            ], 
            "intervention_name": "Glucophage SR tablet 750 mg, Crestor tablet 20 mg", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Metformin", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samgsung Seoul Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomized, Open Label, Multiple-Dose, 6-sequence, 3-period, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Metformin Hydrochloride and Rosuvastatin Calcium in Healthy Male Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Metformin, Rosuvastatin Cmaxss", 
                "safety_issue": "No", 
                "time_frame": "0h(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 24, 48 h of each period (total 16)"
            }, 
            {
                "measure": "metformin, rosuvastatin AUC", 
                "safety_issue": "No", 
                "time_frame": "0h(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 24, 48 h of each period (total 16)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01775579"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Metformin, Rosuvastatin tmaxss", 
                "safety_issue": "No", 
                "time_frame": "0h(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 24, 48 h of each period (total 16)"
            }, 
            {
                "measure": "Metformin, Rosuvastatin t1/2", 
                "safety_issue": "No", 
                "time_frame": "0h(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 24, 48 h of each period (total 16)"
            }, 
            {
                "measure": "Metformin, Rosuvastatin C min,ss", 
                "safety_issue": "No", 
                "time_frame": "0h(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 24, 48 h of each period (total 16)"
            }, 
            {
                "measure": "Metformin, Rosuvastatin CL/Fss", 
                "safety_issue": "No", 
                "time_frame": "0h(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 24, 48 h of each period (total 16)"
            }, 
            {
                "measure": "Metformin, Rosuvastatin Vd/Fss", 
                "safety_issue": "No", 
                "time_frame": "0h(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 24, 48 h of each period (total 16)"
            }
        ], 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}